Tufts CSDD Releases Findings from Diabetes Study
September 26, 2016
According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.
Read the full release here
Recent Videos
Related Content
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025Article
As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
